Jeremy Warner's Outlook: Roche in danger of killing the golden goose
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.If it ain't broke, why break it? Roche's $43.7bn cash offer for the outstanding minority in Genentech risks upsetting a model partnership between big pharma and innovative biotech, an apparently perfect marriage of Roche's marketing might with Genentech's unmatched record in cancer drug discovery, including the breast cancer drug Herceptin. Yet here comes old clumsy clogs with a low ball bid for its beautiful young soulmate.
With Genentech's shares already trading well in advance of the 9 per cent premium Roche is offering, the Swiss parent is going to have to offer quite a bit more to succeed. Biotech buyouts are usually at much bigger premiums, though with 56 per cent of the stock already, Roche plainly doesn't have to pay for control. It already has it.
Even so, nothing could be more stupid than for Roche to get into a standoff with a company so key to its success. There are said to be reasonable synergies involved in a full merger of the operations, and Roche also gets access to Genentech's cash flow. Yet once wholly in the bureaucracy of the mothership, Genentech will lose the independence of management and remuneration that may well underpin its success. Roche needs Genentech's pipeline to compensate for a growing absence in its own. Yet for how much longer will the pipeline thrive once ruled by the dead hand of Big Pharma?
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments